Results 31 to 40 of about 2,500,398 (351)

MicroRNA410 Inhibits Pulmonary Vascular Remodeling via Regulation of Nicotinamide Phosphoribosyltransferase [PDF]

, 2019
Nicotinamide phosphoribosyltransferase (NAMPT) upregulation in human pulmonary artery endothelial cells (hPAECs) is associated with pulmonary arterial hypertension (PAH) progression and pulmonary vascular remodeling.
Chen, Jiwang, Chen, Tianji, Dong, Yangbasai, Gao, Hui, Machado, Roberto F., Song, Yang, Wang, Yifang, Zhao, Shuangping   +7 more
core   +1 more source

MicroRNA-483 amelioration of experimental pulmonary hypertension. [PDF]

, 2020
Endothelial dysfunction is critically involved in the pathogenesis of pulmonary arterial hypertension (PAH) and that exogenously administered microRNA may be of therapeutic benefit.
Bai, Liang, Chen, Shanshan, Chou, Chih-Hung, Cui, Xiaopei, Fan, Fenling, Gongol, Brendan, Gu, Mingxia, He, Ming, He, Yangyang, Huang, Hsien-Da, Jing, Zhi-Cheng, Lei, Yuyang, Li, Zhao, Malhotra, Atul, Miao, Yifei, Rabinovitch, Marlene, Shen, Yuan, Shyy, John Y-J, Wang, Xiaojian, Yan, Xiaosong, Zhang, Jiao, Zhang, Jin, Zhang, Yixin   +22 more
core   +1 more source

Micro-RNA-1 is decreased by hypoxia and contributes to the development of pulmonary vascular remodeling via regulation of sphingosine kinase 1 [PDF]

, 2018
Sphingosine kinase 1 (SphK1) upregulation is associated with pathologic pulmonary vascular remodeling in pulmonary arterial hypertension (PAH), but the mechanisms controlling its expression are undefined.
Chen, Jiwang, Comhair, Suzy, Machado, Roberto F., Natarajan, Viswanathan, Singla, Sunit, Sysol, Justin R., Zhao, Shuangping   +6 more
core   +1 more source

ACVIM consensus statement guidelines for the diagnosis, classification, treatment, and monitoring of pulmonary hypertension in dogs

Journal of Veterinary Internal Medicine, 2020
Pulmonary hypertension (PH), defined by increased pressure within the pulmonary vasculature, is a hemodynamic and pathophysiologic state present in a wide variety of cardiovascular, respiratory, and systemic diseases.
C. Reinero, L. Visser, H. Kellihan, I. Masseau, E. Rozanski, C. Clercx, K. Williams, J. Abbott, M. Borgarelli, B. Scansen   +9 more
semanticscholar   +1 more source

Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. [PDF]

, 2013
BACKGROUND: Riociguat, a member of a new class of compounds (soluble guanylate cyclase stimulators), has been shown in previous clinical studies to be beneficial in the treatment of chronic thromboembolic pulmonary hypertension. METHODS: In this phase 3,
CHEST-1 Study Group,, D'Armini, AM, Fritsch, A, Ghofrani, HA, Grimminger, F, Hoeper, MM, Jansa, P, Kim, NH, Mayer, E, Neuser, D, Simonneau, G, Wang, C, Weimann, G, Wilkins, MR   +13 more
core   +1 more source

Macitentan in daily clinical practice: A single centre, 1-year experience

Pulmonology, 2018
The effectiveness and safety of macitentan, a dual endothelin-receptor antagonist (ERA) approved for the treatment of pulmonary arterial hypertension (PAH), were shown in an extensive clinical trial oriented towards morbidity and mortality events.
S. Cadenas-Menéndez, P. Álvarez-Vega, J. Martín-Moreiras, M. Barreiro-Pérez, M.Á. Gómez-Sánchez, P.L. Sánchez-Fernández   +5 more
doaj   +3 more sources

Metformin reverses development of pulmonary hypertension via aromatase inhibition [PDF]

, 2016
Females are more susceptible to pulmonary arterial hypertension than males, although the reasons remain unclear. The hypoglycemic drug, metformin, is reported to have multiple actions, including the inhibition of aromatase and stimulation of AMP ...
Dean, Afshan, Loughlin, Lynn, MacLean, Margaret R., Nilsen, Margaret, Salt, Ian P.   +4 more
core   +2 more sources

Chronic thromboembolic pulmonary hypertension following long-term peripherally inserted central venous catheter use

Pulmonary Circulation, 2019
A 36-year-old woman presented with recurrent pulmonary emboli (PE) despite oral anticoagulation. She was a type I diabetic with severe gastroparesis requiring insertion of multiple long-term peripherally inserted central catheters (PICC) over a 10-year ...
Abigail Masding, Stephen D. Preston, Mark Toshner, Joseph Barnett, Carl Harries, Konstantinos Dimopoulos, Aleksander Kempny, Colm McCabe, David P. Jenkins, S. John Wort, Laura C. Price   +10 more
doaj   +1 more source

Effects of novel muscarinic M3 receptor ligand C1213 in pulmonary arterial hypertension models. [PDF]

, 2016
Pulmonary hypertension (PH) is a complex disease comprising a pathologic remodeling and thickening of the pulmonary vessels causing an after load on the right heart ventricle that can result in ventricular failure. Triggered by oxidative stress, episodes
Ahmed, Mohamed, Al-Abed, Yousef, Coleman, Thomas, Lakshminrusimha, Satyanarayana, Patel, Hardik, VanPatten, Sonya   +5 more
core   +2 more sources

Pulmonary Hypertension [PDF]

JAMA, 2012
Pulmonary hypertension (PH), defined as elevated pulmonary artery pressure, is common in the general population and associated with increased mortality. Accordingly, physicians commonly encounter patients with dyspnea, exercise intolerance, and/or right heart failure who have elevated pulmonary artery systolic pressure (PASP) on echocardiography ...
Ilknur Basyigit, Gulfer Okumus, Serpil Erzurum, Kewal Asosingh, Despina Papakosta   +4 more
openaire   +5 more sources